Nicotine Dependence Clinical Trial
Official title:
The Gender-Sex Hormone Interface With Craving & Stress-Related Changes in Smoking
The purpose of the overall parent study is to determine the impact of gender and hormones
(estradiol, progesterone, testosterone and cortisol) on responses to stress and smoking cues
presented in daily, "real-world" cue presentations compared to a final cue session in a lab.
In addition, in the portion of the study that incorporates clinical trials elements and is
reported here, the study will examine the impact of a single dose of oxytocin (chemical
produced in the body) versus placebo (inactive substance) on reactivity to a stress procedure
(Trier Social Stress Task) in smokers.
The overall parent study involves a cue presentation technology known as "CREMA" (Cue
Reactivity Ecologic Momentary Assessment) which delivers four daily cue presentations to you
on a handheld device during your everyday routine. Additionally, the study involves daily
collection of saliva samples for hormonal testing. These daily procedures will provide
information about the role of cues and hormones in daily life. The clinical trial portion of
the study (reported here) consists of measures collected within the laboratory.
Despite considerable advances in treatment development, cigarette smoking remains the leading
cause of preventable death in the United States, and most smokers engaged in treatment are
unsuccessful in quitting. The burden of illness is disproportionately borne by female
smokers, who are less responsive to cessation interventions than males. The relationships
between stress, craving, and smoking behavior are recognized as key factors underlying gender
differences in nicotine dependence, but must be better understood and characterized to yield
avenues for interventions addressing this critical health disparity.
In prior and ongoing SCOR studies, our research team has demonstrated gender and menstrual
cycle/sex hormone influences on reactivity to laboratory-presented cues. Building from these
laboratory findings, we propose taking two important next steps: (1) evaluating the
experience of craving in the "real world" natural environment of female and male smokers, and
(2) examining the impact of a safe and novel pharmacological intervention (oxytocin) on
stress reactivity in female and male smokers.
If, as hypothesized, gender, sex hormones, and oxytocin administration influence the
relationships between stress, craving, and smoking behavior, the findings could substantially
address a key gender-related health disparity. Such knowledge could also inform the
development of gender-specific interventions to enhance female smokers' response to cessation
treatments. Therefore, the knowledge to be gained from the proposed study may yield
significant public health benefits.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05176418 -
IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate
|
Early Phase 1 | |
Completed |
NCT04084210 -
Impact of Alternative Nicotine-Delivery Products on Combustible Cigarette Use
|
Phase 2 | |
Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
Withdrawn |
NCT03707600 -
State and Trait Mediated Response to TMS in Substance Use Disorder
|
N/A | |
Recruiting |
NCT03999099 -
Targeting Orexin to Treat Nicotine Dependence
|
Phase 1 | |
Completed |
NCT03847155 -
Prevention of Nicotine Abstinence in Critically Ill Patients After Major Surgery
|
N/A | |
Completed |
NCT02840435 -
Study on Sit to Quit Phone Intervention
|
N/A | |
Completed |
NCT02139930 -
Project 2: Strategies for Reducing Nicotine Content in Cigarettes
|
N/A | |
Completed |
NCT01982110 -
A Mindfulness Based Application for Smoking Cessation
|
N/A | |
Completed |
NCT01926626 -
Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers
|
Phase 2 | |
Withdrawn |
NCT01569477 -
Striving to Quit-Wisconsin Tobacco Quit Line
|
N/A | |
Completed |
NCT01569490 -
Striving to Quit: First Breath
|
N/A | |
Completed |
NCT01685996 -
Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation
|
Phase 1/Phase 2 | |
Completed |
NCT01632189 -
The Effect of Varenicline on D2/D3 Receptor Binding in Smokers
|
N/A | |
Active, not recruiting |
NCT01182766 -
New Treatment for Alcohol and Nicotine Dependence
|
Phase 2/Phase 3 | |
Completed |
NCT00996034 -
Nicotine Vaccination and Nicotinic Receptor Occupancy
|
Phase 2 | |
Completed |
NCT01061528 -
Coping Skills Treatment for Smoking Cessation
|
N/A | |
Withdrawn |
NCT01589081 -
Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect
|
N/A | |
Completed |
NCT01943994 -
Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study
|
N/A | |
Suspended |
NCT01636336 -
Effects of Progesterone on Smoked Nicotine Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effects
|
N/A |